Myocardial Infarction and Late-Onset Epilepsy: Unraveling Bidirectional Vascular Risks in Aging Populations
Posted inCardiology Clinical Updates Neurology news

Myocardial Infarction and Late-Onset Epilepsy: Unraveling Bidirectional Vascular Risks in Aging Populations

Emerging cohort evidence reveals myocardial infarction significantly elevates late-onset epilepsy risk, with late-onset epilepsy also predicting subsequent myocardial infarction and vascular mortality, underscoring shared systemic vascular pathology and implications for integrated vascular risk management.
Metformin Exposure Associated with Up to 81% Lower 30‑Day Mortality After Cardiac Surgery in T2DM: A Critical Appraisal of AHA 2025 MIMIC‑IV Cohort Findings
Posted inCardiology Diabetes & Endocrinology news

Metformin Exposure Associated with Up to 81% Lower 30‑Day Mortality After Cardiac Surgery in T2DM: A Critical Appraisal of AHA 2025 MIMIC‑IV Cohort Findings

A retrospective MIMIC‑IV cohort presented at AHA 2025 found perioperative metformin exposure in T2DM patients undergoing cardiac surgery associated with markedly lower 30‑, 90‑ and 360‑day mortality. Results are compelling but observational—randomized trials are needed to confirm causality and define perioperative use.
RSV prefusion F bivalent vaccine protects older adults similarly whether or not they have atherosclerotic cardiovascular disease
Posted inCardiology news Respiratory

RSV prefusion F bivalent vaccine protects older adults similarly whether or not they have atherosclerotic cardiovascular disease

In a prespecified secondary analysis of the DAN‑RSV randomized trial, the bivalent RSV prefusion F vaccine showed comparable effectiveness against RSV‑related respiratory hospitalizations in adults ≥60 years with and without pre‑existing atherosclerotic cardiovascular disease (ASCVD); no clear reduction in major adverse cardiovascular events was observed.
Percutaneous Strategy (TAVI + FFR-guided PCI) Outperforms SAVR + CABG at 1 Year in Patients ≥70 with Severe Aortic Stenosis and Complex Coronary Disease: Results of the TCW Randomised Trial
Posted inCardiology news

Percutaneous Strategy (TAVI + FFR-guided PCI) Outperforms SAVR + CABG at 1 Year in Patients ≥70 with Severe Aortic Stenosis and Complex Coronary Disease: Results of the TCW Randomised Trial

The TCW trial randomized 172 patients ≥70 years with severe aortic stenosis and complex coronary disease to FFR-guided PCI plus TAVI versus SAVR plus CABG. At 1 year the percutaneous strategy met non-inferiority and demonstrated superiority for a composite endpoint driven by lower mortality and life‑threatening bleeding.
Transseptal TMVR with the SAPIEN M3 Lowers 1‑Year Mortality/HF Rehospitalisation in Patients Unsuitable for Surgery or TEER
Posted inCardiology news

Transseptal TMVR with the SAPIEN M3 Lowers 1‑Year Mortality/HF Rehospitalisation in Patients Unsuitable for Surgery or TEER

A multicountry, single‑arm pivotal trial of the SAPIEN M3 transseptal transcatheter mitral valve replacement (TMVR) in patients deemed unsuitable for surgery or TEER demonstrated a 1‑year composite rate of death or heart‑failure rehospitalisation of 25.2%, significantly below the prespecified 45% performance goal, with few intraprocedural complications.
Liberal vs Restrictive Postoperative Transfusion in High-Cardiac-Risk Surgery: TOP Trial Shows No Mortality or Major Ischemic Benefit
Posted inCardiology General Surgery news

Liberal vs Restrictive Postoperative Transfusion in High-Cardiac-Risk Surgery: TOP Trial Shows No Mortality or Major Ischemic Benefit

In high–cardiac-risk veterans after major vascular or general surgery, a liberal postoperative transfusion threshold (Hb <10 g/dL) did not reduce 90‑day death or major ischemic events compared with a restrictive threshold (Hb <7 g/dL); some non‑MI cardiac complications were less frequent with liberal transfusion.
Daily Caffeinated Coffee After Cardioversion Cuts Atrial Fibrillation Recurrence: Results from the DECAF Randomized Trial
Posted inCardiology news

Daily Caffeinated Coffee After Cardioversion Cuts Atrial Fibrillation Recurrence: Results from the DECAF Randomized Trial

The DECAF randomized trial found that encouraging caffeinated coffee consumption (≈1 cup/day) after successful cardioversion reduced clinically detected AF/flutter recurrence over 6 months versus caffeine abstinence (47% vs 64%; HR 0.61). Results challenge routine caffeine restriction in AF patients but require confirmation and contextualization.